Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series

- Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone - - Data support the

Related Keywords

China ,United States ,Shanghai ,Canada ,Patricia Keegan ,Pabout Toripalimab ,Mcdavid Stilwell ,Junshi Biosciences ,Theresa Lavallee ,Coherus Biosciences ,Zhi Li ,Kelli Perkins ,Exchange Commission On ,Ir Team ,Coherus Biosciences Inc ,Exchange Commission ,National Reimbursement Drug List ,National Medical Products Administration ,Pr Team ,Chief Medical Officer ,Chief Development Officer ,Southeast Asia ,New Drug Applications ,Prescription Drug User Fee Act ,Breakthrough Therapy ,Fast Track ,Private Securities Litigation Reform Act ,Coheru Annual Report ,Press Release ,Junshi ,Iosciences ,Coherus ,Nnounce ,Presentation ,Positive ,Results ,Rom ,Choice ,Hase ,Linical ,Trial ,Valuating ,Toripalimab ,Combination ,Chemotherapy ,First ,Line ,Treatment ,Mall ,Fell ,Young ,